Immune cell boost may keep leukemia at bay after transplant

NCT ID NCT07237230

Recruiting now Disease control Sponsor: Donghua Zhang Source: ClinicalTrials.gov ↗

First seen Nov 19, 2025 · Last updated May 21, 2026 · Updated 24 times

Summary

This study tests whether giving patients special immune cells (γδ T cells) from a donor can help prevent their high-risk acute myeloid leukemia from returning after a stem cell transplant. About 40 adults aged 18 to 65 will receive the cell infusion and be monitored for safety and how long they stay cancer-free. The goal is to see if this approach can reduce the chance of relapse without causing serious side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIGH RISK ACUTE MYELOID LEUKEMIA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology
RECRUITING

Wuhan, Hubei, 430000, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

HIGH RISK ACUTE MYELOID LEUKEMIA